Aceso Life Science Group Limited (0474.HK)
HKD 0.04
(0.0%)
HKD 0.04
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 666 Million HKD | 245.08% |
| 2022 | 193 Million HKD | -77.92% |
| 2021 | 874 Million HKD | -55.52% |
| 2020 | 1.96 Billion HKD | 37.82% |
| 2019 | 1.42 Billion HKD | -21.4% |
| 2018 | 1.81 Billion HKD | 199.66% |
| 2017 | 605.34 Million HKD | 204.11% |
| 2016 | 199.05 Million HKD | 20.97% |
| 2015 | 164.55 Million HKD | 13.84% |
| 2014 | 144.55 Million HKD | 932.5% |
| 2013 | 14 Million HKD | 0.0% |
| 2012 | - HKD | 0.0% |
| 2011 | - HKD | -100.0% |
| 2010 | 217.83 Million HKD | -41.01% |
| 2009 | 369.29 Million HKD | 0.0% |
| 2008 | - HKD | 0.0% |
| 2007 | - HKD | 0.0% |
| 2006 | - HKD | 0.0% |
| 2005 | - HKD | -100.0% |
| 2004 | 822 Thousand HKD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 Q4 | 666 Million HKD | 0.0% |
| 2023 Q1 | 685 Million HKD | 254.92% |
| 2023 Q2 | 141 Million HKD | -79.42% |
| 2023 Q3 | 666 Million HKD | 372.34% |
| 2023 FY | 666 Million HKD | 245.08% |
| 2022 Q4 | 193 Million HKD | -74.47% |
| 2022 Q3 | 756 Million HKD | 202.4% |
| 2022 FY | 193 Million HKD | -77.92% |
| 2022 Q1 | 789 Million HKD | -9.73% |
| 2022 Q2 | 250 Million HKD | -68.31% |
| 2021 Q2 | 1.82 Billion HKD | -26.94% |
| 2021 FY | 874 Million HKD | -55.52% |
| 2021 Q1 | 2.49 Billion HKD | 26.92% |
| 2021 Q4 | 874 Million HKD | 1.98% |
| 2021 Q3 | 857 Million HKD | -52.96% |
| 2020 Q3 | 1.94 Billion HKD | 35.21% |
| 2020 Q1 | 1.41 Billion HKD | -0.55% |
| 2020 FY | 1.96 Billion HKD | 37.82% |
| 2020 Q4 | 1.96 Billion HKD | 0.92% |
| 2020 Q2 | 1.44 Billion HKD | 1.55% |
| 2019 Q2 | 1.73 Billion HKD | 0.39% |
| 2019 FY | 1.42 Billion HKD | -21.4% |
| 2019 Q4 | 1.42 Billion HKD | 1.99% |
| 2019 Q3 | 1.39 Billion HKD | -19.27% |
| 2019 Q1 | 1.72 Billion HKD | -4.91% |
| 2018 Q1 | 1.41 Billion HKD | 134.36% |
| 2018 Q4 | 1.81 Billion HKD | 2.45% |
| 2018 Q3 | 1.77 Billion HKD | 24.24% |
| 2018 Q2 | 1.42 Billion HKD | 0.45% |
| 2018 FY | 1.81 Billion HKD | 199.66% |
| 2017 Q4 | 605.34 Million HKD | 14.06% |
| 2017 FY | 605.34 Million HKD | 204.11% |
| 2017 Q3 | 530.72 Million HKD | 55.09% |
| 2017 Q2 | 342.21 Million HKD | -23.22% |
| 2017 Q1 | 445.73 Million HKD | 123.93% |
| 2016 Q2 | 164.55 Million HKD | -38.39% |
| 2016 Q4 | 199.05 Million HKD | -21.58% |
| 2016 Q3 | 253.84 Million HKD | 54.26% |
| 2016 FY | 199.05 Million HKD | 20.97% |
| 2016 Q1 | 267.07 Million HKD | 62.31% |
| 2015 FY | 164.55 Million HKD | 13.84% |
| 2015 Q3 | 255.84 Million HKD | 55.48% |
| 2015 Q4 | 164.55 Million HKD | -35.68% |
| 2015 Q2 | 164.55 Million HKD | -35.68% |
| 2015 Q1 | 255.84 Million HKD | 76.99% |
| 2014 Q2 | 99.55 Million HKD | 0.0% |
| 2014 FY | 144.55 Million HKD | 932.5% |
| 2014 Q4 | 144.55 Million HKD | 0.0% |
| 2014 Q1 | 99.55 Million HKD | 611.07% |
| 2014 Q3 | 144.55 Million HKD | 45.2% |
| 2013 Q4 | 14 Million HKD | 0.0% |
| 2013 FY | 14 Million HKD | 0.0% |
| 2013 Q1 | - HKD | 0.0% |
| 2013 Q2 | - HKD | 0.0% |
| 2013 Q3 | 14 Million HKD | 0.0% |
| 2012 Q2 | - HKD | 0.0% |
| 2012 FY | - HKD | 0.0% |
| 2012 Q1 | - HKD | 0.0% |
| 2012 Q3 | - HKD | 0.0% |
| 2012 Q4 | - HKD | 0.0% |
| 2011 Q2 | 511.58 Million HKD | 0.0% |
| 2011 Q4 | - HKD | 0.0% |
| 2011 FY | - HKD | -100.0% |
| 2010 Q4 | 217.83 Million HKD | 0.0% |
| 2010 Q2 | 321.57 Million HKD | 0.0% |
| 2010 FY | 217.83 Million HKD | -41.01% |
| 2009 FY | 369.29 Million HKD | 0.0% |
| 2009 Q4 | 369.29 Million HKD | 0.0% |
| 2008 FY | - HKD | 0.0% |
| 2007 FY | - HKD | 0.0% |
| 2006 FY | - HKD | 0.0% |
| 2005 FY | - HKD | -100.0% |
| 2004 FY | 822 Thousand HKD | 0.0% |